Sign In
Buy MKGAF
$149.28
-7.84 (-4.99%)
At Close: Jun 22, 2026
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
10:40am, Monday, 18'th May 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript
10:50pm, Wednesday, 13'th May 2026
Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript
Merck KGaA Q1 Earnings Call Highlights
10:08am, Wednesday, 13'th May 2026
Merck KGaA ETR: MRK reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised
Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates
08:11am, Wednesday, 13'th May 2026
Merck KGaA (MKKGY) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.59 per share a year ago.
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
08:05am, Thursday, 30'th Apr 2026
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT0
Merck KGaA: Small Breakout In 2026, Followed By Normalization
09:48pm, Sunday, 26'th Apr 2026
Merck KGaA is rated a 'Buy' with a revised price target of €127/share, reflecting strong fundamentals and resilient business segments. I expect 2026 to be a transition year with AEPS decline due to
Head-To-Head Analysis: Merck KGaA (OTCMKTS:MKGAF) vs. Athersys (NASDAQ:ATHX)
02:43am, Saturday, 28'th Mar 2026
Earnings and Valuation This table compares Athersys and Merck KGaA"s gross revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TrumpRx lists many medicines at prices higher than paid in UK
02:23pm, Wednesday, 18'th Mar 2026
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
Merck KGaA (OTCMKTS:MKGAF) & Calithera Biosciences (NASDAQ:CALA) Head to Head Contrast
02:23am, Monday, 09'th Mar 2026
Institutional and Insider Ownership 0.1% of Merck KGaA shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is
Merck KGaA (MKKGY) Q4 2025 Earnings Call Transcript
05:45pm, Thursday, 05'th Mar 2026
Merck KGaA (MKKGY) Q4 2025 Earnings Call Transcript
Merck KGaA (MKKGY) Q4 2025 Press Conference Call Transcript
12:16pm, Thursday, 05'th Mar 2026
Merck KGaA (MKKGY) Q4 2025 Press Conference Call Transcript
Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO
02:08am, Thursday, 12'th Feb 2026
Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.
Financial Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) versus Merck KGaA (OTCMKTS:MKGAF)
01:10am, Sunday, 01'st Feb 2026
Risk and Volatility Virpax Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Merck KGaA has a beta of 0.96, meaning that its share
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:15pm, Tuesday, 13'th Jan 2026
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Financial Comparison: Merck KGaA (OTCMKTS:MKGAF) versus AEON Biopharma (NASDAQ:AEON)
02:14am, Sunday, 21'st Dec 2025
AEON Biopharma (NASDAQ: AEON - Get Free Report) and Merck KGaA (OTCMKTS:MKGAF - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based
